

CytoDyn (CYDY)

SEC Must Immediately Halt this Stock Promotion Scheme

We cannot remember the last time we've seen a bigger joke of a stock. This is a \$5 billion market cap company with 10 employees who claims to have the cure for COVID with zero data and a CEO who sold >\$30 million of stock ~70% lower than yesterday's closing stock price.

The CEO has made inappropriate promotional claims like *"this looks the solution to coronavirus"* leading into his most recent stock sale.

On Feb 4th, 2020, the SEC issued an [Investor Alert](#) warning about COVID-related stock promotions. CytoDyn, a Vancouver based OTC-listed biotech company, appears to be one such stock promotion. The brazen stock promotion scheme should immediately be halted by the SEC.

Culper Research has also done good work here which covers the history of the company in more detail.

https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_CYDY_2-6-2020.pdf?ver=1591103388830

https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_CYDY_2-12-2020.pdf?ver=1591103388830

https://img1.wsimg.com/blobby/go/cc91fda7-4669-4d1b-81ce-a0b8d77f25ab/downloads/Culper_CYDY_5-8-2020.pdf?ver=1591103388830

CytoDyn has aggressively touted its investigational drug candidate, Leronlimab, as a potential treatment for COVID-19. However, there is zero scientific data to support this view. This has not prevented the company from making several misleading and disingenuous claims in an effort to generate hype around their drug candidate and stock price.

So far this year, CytoDyn has issued 51 press releases, conducted 5 conference calls, participated in no less than 24 interviews, and has utilized several third-party investor relations and stock newsletter services.

CytoDyn has used the increased attention to raise capital multiple times since January 2020. The company has regularly employed selective and incomplete disclosure in order to continue to promote the stock.

Below are the red flags that should be on the radar of the SEC:

- On April 27, 2020, CytoDyn held its latest investor conference call. Jacob Lalezari, the company's interim Chief Medical Officer (CMO) made several statements implying Leronlimab's efficacy in treating patients with COVID. Not only are these claims highly inappropriate given the lack of available data, Lalezari was presented as an independent medical authority with no financial interest in CytoDyn
 - ***"It's clear this drug is working, working better than we ever could have imagined. The sooner we bring relief to people, the better"***
 - ***"I think we've shown this could be the one drug that does it all"***
 - ***"There's no doubt in my mind anymore about how important this drug is going to be for COVID-19"***
- On the same conference call, CEO Nader Pourhassan said that he believed his mother-in-law was alive because of Leronlimab treatment. Though the Leronlimab trial received clearance in Nov 2018 and expects to enroll 48 patients, enrollment thus far has been just 3, of which 1 is the CEO's mother-in-law
 - In the absence of real clinical data, the company relies on buzzy anecdotal reports and makes grandiose claims such as ***"the patient is somebody close to me, in San Jose. This patient was ... essentially [on] life support ... and is now close to being off ventilator and they've already made plans to ship her to rehab to continue her care and physical therapy"*** (2:36, Apr 30th, 2020 [Proactive Investors](#))
- Prior to the April 27 call, the COVID-19 thesis put forth by management was that Leronlimab would aid in suppressing the cytokine storm which has been leading to complications in many cases. Before this point, Leronlimab was not framed as anti-viral. On April 24, a [letter to the editor](#) was published in the NEJM that included data from Kidney-transplant recipients that had been infected with COVID-19. 6 of 36 patients were administered Leronlimab. Only 1 those patients remained in stable condition without intubation. CytoDyn management failed to mention this important fact on their April 27 call despite indicating that the NEJM publication was one of the subjects of the call. They did briefly mention the reduction in IL-6 levels in treated patients, but failed to mention the clinical outcomes. Instead, the company pivoted its thesis and claimed that Leronlimab has been associated with reduction in viral load observed in blood plasma. This appears to be a bait and switch whereby management is attempting to avoid disclosing any negative information to investors. When asked to

elaborate on their new breakthrough by a participant on the call, the CEO refuses to provide any additional detail and ends the Q&A shortly thereafter

- On April 27, Sanofi / Regeneron [announced](#) disappointing results from their phase 2 trial testing Kevzara (an IL-6 inhibitor) on COVID-19 patients. This has potential read-through to CytoDyn's original hopes for Leronlimab, which is likely another reason the company decided to pivot away from their original thesis
- CytoDyn's March 16 press release indicates Leronlimab is being explored as *"therapy for patients who experience respiratory complications"* from COVID-19. There is no mention of anti-viral properties at any point before the April 27 call
- While CytoDyn continues to avoid disseminating any negative news to investors, the company never wastes an opportunity to tout anecdotal COVID-19 success stories. This selective disclosure is alarming because it fails to portray an accurate picture to investors. To-date the company has not disclosed full data from the patients they have treated
 - ***"patients with mild-moderate disease were given a dose of leronlimab, they very quickly come off oxygen. We have many patients now who were intubated, they were given a dose of leronlimab, they come off intubation"*** (6:29, Apr 13th, 2020 [Proactive Investors](#))
 - In response to why the HIV BLA hasn't yet been submitted: *"saving these peoples lives today is the most urgent thing we could be doing ... we said "ok lets try it" and so we had to put all of our team to save peoples lives. Thank you, the shareholders, for allowing the company to be at this point to be able to do that. **So we saved some lives, its been on the news, it's no fluke or hoax, it happened**"* (4:11). *"For the good of the humanity we're going to try it and now **it looks like, to me, that this is the solution to coronavirus**"* (5:30, Apr 15th, 2020 [Proactive Investors](#))
 - *"at the end of the day that [offering some ray of hope to help save the lives of loved ones] is what keeps CytoDyn working, it's always been a company with huge heart and a major focus on patients and it's also something that **keeps us working long hours in the lab to figure this disease out, and I think we have ... the results explain themselves**"* (8:05, Apr 30th, 2020 [Proactive Investors](#))
- The company has stated several times that it recently raised capital in the form of debt convertible into stock at \$4.50 per share with no warrants.

The company has attempted to frame this as validation of their success – the supposed ability to raise external capital at favorable terms. However, what CytoDyn fails to mention is that the convertible note has a reset feature – its conversion price gets adjusted down to wherever the company’s next equity deal gets priced. As a result, the sticker price of the convertible financing is largely irrelevant. Furthermore, the financing included an original issuer discount (OID) of \$2.1 million, representing ~12% of the total principal amount of the financing. Iliad Research and Trading has a history of financing questionable public microcap entities with similar structured financings

- On April 28, 2020, CytoDyn disclosed that shareholders, including three former Board Members, had filed a lawsuit against CytoDyn for unjust enrichment. The three former Board Members include Anthony Caracciolo (2012-2019), Greg Gould (2007-2019), and Carl Dockery (2014-2019), where all three resigned in 2019. Part of the complaint is related to a contingent share award disclosed on January 28, 2020 whereby management was to be granted 11.65m shares (currently worth >US\$30m) if CytoDyn achieves breakthrough designation within 6 months. The value of this award is egregious relative to the milestone involved and the pre-revenue nature of the company. This award supports the view that CytoDyn is a stock promotion scheme intended to enrich insiders
- Days later, on Apr 30th, 2020, CytoDyn filed an **S-3/A which includes 2 million \$0.63 warrants issued to CEO Nader Pourhassan in connection with the above-mentioned share grant [S-3/A](#)**. The S-3 also listed Michael McCarthy from the Dream Team Group, a former stock promotion scheme exposed by Adam Feuerstein and Richard Pearson [Buysstrike](#)
- **CEO Nader Pourhassan ultimately sold ~10 million shares (>\$30 million) between Apr 30th and May 4th**
- There is an alarming level of management and board turnover as well as troubling allegations that the CEO has ignored concerns around patient safety from the company’s former CMO. This struggle resulted in three additional board member resignations and was well-highlighted in a lawsuit filed by the same CMO (lawsuit number: 1:19-cv-01563-RGA). Several of these resigned board members are involved in the above-referenced unjust enrichment lawsuit

		Significant 2H19/1H20 Turnover				
Age	Name	FY16	FY17	FY18	FY19	FY20
Management						
n/a	Craig S. Eastwood				VP CFO	
67	Nitya G. Ray				CTO	
62	Richard G. Pestell				Chief Medical Officer	1
78	Denis R. Burger	Chief Science Officer				
68	Michael D. Mulholland	CFO, Treasurer, Corporate Secretary (util Nov. 2019)				
57	Nader Z. Pourhassan	CEO				
Board						
n/a	Samir Patel					Director
n/a	Alan P. Timmins					Director
59	David F. Welch				Director	
62	Richard G. Pestell				Director	
55	Michael A. Klump				Director	
50	Scott A. Kelly		Director		Chairman	
57	Nader Z. Pourhassan	President				
60	Jordan Naydenov	Director				
54	Gregory A. Gould	Director				
58	Carl C. Dockery	Director				
65	Anthony D. Caracciolo	Director	Chairman			1
68	Bruce A. Montgomery	Director				
78	Denis R. Burger	Director				

Cautious Investing to All

These reports have been prepared by either Citron Research (“Citron Research”) or Citron Capital, LLC (“Citron Capital”). Citron Research and Citron Capital are referred to collectively as “Citron” and each individually as a “Citron Entity.” Each report specifies the publisher and owner of that report. All reports are for informational purposes only and presented “as is” with no warranty of any kind, express or implied. Under no circumstances should any of these reports or any information herein be construed as investment advice, or as an offer to sell or the solicitation of an offer to buy any securities or other financial instruments.

Citron Research produces research reports on publicly traded securities, and Citron Capital is an exempt reporting adviser filed with the California Department of Business Oversight. The reports are the property of the applicable Citron Entity that published that report. The opinions, information and reports set forth herein are solely attributable to the applicable Citron Entity and are not attributable to any Citron Related Person (defined below) (other than the Citron Entity that published the report).

By downloading, accessing, or viewing any research report, you agree to the following Terms of Use. You agree that use of the research presented in any report is at your own risk. You (or any person you are acting as agent for) agree to hold harmless Citron Research, Citron Capital and each of their affiliates and related parties, including, but not limited to any principals, officers, directors, employees, members, clients, investors, consultants and agents (collectively, the “Citron Related Persons”) for any direct or indirect losses (including trading losses) attributable to any information in a research report. You further agree to do your own research and due diligence before making any investment decision with respect to securities of the issuers covered herein (each, a “Covered Issuer”) or any other financial instruments that reference the Covered Issuer or any securities issued by the Covered Issuer. You represent that you have sufficient investment sophistication to critically assess the information, analysis and opinion presented in any Citron report. You further agree that you will not communicate the contents of reports and other materials made available by Citron to any other person unless that person has agreed to be bound by these Terms of Use. If you access, download or receive the contents of Citron reports or other materials on your own behalf, you agree to and shall be bound by these Terms of Use. If you access, download or receive the contents of Citron reports or other materials as an agent for any other person, you are binding your principal to these same Terms of Use.

As of the publication date of a Citron report, Citron Related Persons (possibly along with or through its members, partners, affiliates, employees, and/or consultants), Citron Related Persons clients and/or investors and/or their clients and/or investors have a position (long or short) in one or more of the securities of a Covered Issuer (and/or options, swaps, and other derivatives related to one or more of these securities), and therefore may realize significant gains in the event that the prices of a Covered Issuer's securities decline or appreciate. Citron Research, Citron Capital and/or the Citron Related Persons may continue to transact in Covered Issuers' securities for an indefinite period after an initial report on a Covered Issuer, and such position(s) may be long, short, or neutral at any time hereafter regardless of their initial position(s) and views as stated in the Citron research. Neither Citron Research nor Citron Capital will update any report or information to reflect changes in positions that may be held by a Citron Related Person.

This is not an offer to sell or a solicitation of an offer to buy any security. Neither Citron Research nor any Citron Related Person (including Citron Capital) are offering, selling or buying any security to or from any person through any Citron research reports. Citron Research is affiliated with Citron Capital. Citron Capital is an exempt reporting adviser filed with the California Department of Business Oversight and is not registered as investment adviser in any other jurisdiction. Citron Capital does not render investment advice to anyone unless it has an investment adviser-client relationship with that person evidenced in writing. You understand and agree that Citron Capital does not have any investment advisory relationship with you or does not owe fiduciary duties to you. Giving investment advice requires knowledge of your financial situation, investment objectives, and risk tolerance, and Citron Capital has no such knowledge about you.

The research and reports made available by Citron reflect express the opinion of the applicable Citron Entity as of the time of the report only. Reports are based on generally available information, field research, inferences and deductions through the applicable Citron Entity's due diligence and analytical process. To the best of the applicable Citron Entity's ability and belief, all information contained herein is accurate and reliable, is not material non-public information, and has been obtained from public sources that the applicable Citron Entity believe to be accurate and reliable, and who are not insiders or connected persons of the Covered Issuers or who may otherwise owe a fiduciary duty, duty of confidentiality or any other duty to the Covered Issuer (directly or indirectly). However, such information is presented "as is," without warranty of any kind, whether express or implied. With respect to their respective research reports, Citron Research and Citron Capital makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. Further, any research report contains a very large measure of analysis and opinion. All expressions of opinion are subject to change without notice, and Citron does not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them.

In no event shall Citron Research, Citron Capital or any Citron Related Persons be liable for any claims, losses, costs or damages of any kind, including direct, indirect, punitive, exemplary, incidental, special or, consequential damages, arising out of or in any way connected with any information presented in any Citron report. This limitation of liability applies regardless of any negligence or gross negligence of Citron Research, Citron Capital or any Citron Related Persons. You accept all risks in relying on the information presented in any report.

You agree that the information in any Citron research report is copyrighted, and you therefore agree not to distribute this information in any manner without the express prior written consent of the applicable Citron Entity. If you have obtained Citron research reports in any manner other than as provided by Citron, you may not read such research without agreeing to these Terms of Use. You further agree that any dispute between you and Citron and their affiliates arising from or related to this report or viewing the material presented herein shall be governed by the laws of the State of California, without regard to any conflict of law provisions. The failure of Citron Research or Citron Capital to exercise or enforce any right or provision of these Terms of Use shall not constitute a waiver of this right or provision. You agree that each Citron Related Person is a third-party beneficiary to these Terms of Use. If any provision of these Terms of Use is found by a court of competent jurisdiction to be invalid, the parties nevertheless agree that the court should endeavor to give effect to the parties' intentions as reflected in the provision and rule that the other provisions of these Terms of Use remain in full force and effect, in particular as to this governing law and jurisdiction provision. You agree that regardless of any statute or law to the contrary, any claim or cause of action arising out of or related to Citron report or related material must be filed within one (1)

year after the occurrence of the alleged harm that gave rise to such claim or cause of action, or such claim or cause of action be forever barred.